Maxwell D M, Vlahacos C P, Lenz D E
United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010-5425.
Toxicol Lett. 1988 Oct;43(1-3):175-88. doi: 10.1016/0378-4274(88)90027-6.
A pharmacodynamic model for inhibition of acetylcholinesterase (AChE) by soman was developed to describe the intertissue differences in AChE inhibition, the dose response of AChE to inhibition by soman, and the effect of differences in xenobiotic metabolism on soman toxicity. Based on the principles of physiological pharmacokinetics, this pharmacodynamic model consisted of a set of mass balance equations that included parameters for blood flow, tissue volumes, soman metabolism, tissue/plasma partition coefficients, initial AChE levels, and the rate constant for AChE inhibition. Sensitivity analysis of the model revealed that variation of the soman metabolism parameter in plasma was the most important determinant of variation in the inhibition of brain AChE by soman.
建立了沙林抑制乙酰胆碱酯酶(AChE)的药效学模型,以描述AChE抑制的组织间差异、AChE对沙林抑制的剂量反应以及外源性物质代谢差异对沙林毒性的影响。基于生理药代动力学原理,该药效学模型由一组质量平衡方程组成,这些方程包括血流参数、组织体积、沙林代谢、组织/血浆分配系数、初始AChE水平以及AChE抑制的速率常数。模型的敏感性分析表明,血浆中沙林代谢参数的变化是沙林抑制脑AChE变化的最重要决定因素。